Ranbaxy to resume generic Lipitor production for U.S

Fri Feb 22, 2013 11:01pm IST

Related Topics

Stocks

   

REUTERS - Generic drugmaker Ranbaxy Laboratories Ltd (RANB.NS) said on Friday it will resume production of its version of Pfizer's (PFE.N) cholesterol fighter Lipitor for sale in the United States after resolving the issues that led to a November recall.

Ranbaxy in November recalled its atorvastatin from the U.S. market and stopped manufacturing the widely used cholesterol lowering medicine after the company discovered contamination with tiny glass particles in certain lots of 10 milligram, 20 mg and 40 mg doses of the drug. Atorvastatin is the generic name for Lipitor.

"We are working with the U.S. FDA, and have identified and implemented multiple corrective and preventative actions," Ranbaxy spokesman Chuck Capriello said in an e-mailed statement.

"As part of the first step in initiating the manufacturing process to resume supplies to the U.S. market, we have commenced the production of the drug substance for our atorvastatin product," he added.

The recall and production halt did not affect Ranbaxy's atorvastatin supply for markets outside the United States, the company said.

During its first six months on the market, atorvastatin generated sales of nearly $600 million for Ranbaxy, according to industry analyst estimates.

Prior to expiration of Pfizer's patent, Lipitor was the world's top selling prescription medicine with annual peak sales of about $13 billion for the largest U.S. drugmaker.

Ranbaxy has been operating under heightened scrutiny to ensure it meets good manufacturing practices following a series of manufacturing problems that nearly derailed it ability to sell atorvastatin in the United States.

In 2008, the FDA banned the company from importing about 30 drugs after it found manufacturing deficiencies at two of the company's facilities in India, and Ranbaxy was later accused of falsifying data used in its drug applications.

Ranbaxy said on Friday that it was confident in the continuing safety and quality of its products.

(Reporting by Bill Berkrot;editing by Sofina Mirza-Reid)

FILED UNDER:

Religion and Politics

REUTERS SHOWCASE

Fund Raising

Fund Raising

Flipkart raises $700 million in fresh funding.   Full Article 

Reforms Push

Reforms Push

Modi may order insurance, coal reforms if vote delayed - officials.  Full Article 

Reuters Exclusive

Reuters Exclusive

India looks to sway Americans with nuclear power insurance plan  Full Article 

To Boost Growth

To Boost Growth

Crank up public spending to revive growth - chief economic adviser.   Full Article 

Bold Steps

Bold Steps

SpiceJet rescue plan marks bold bet on Indian aviation recovery.   Full Article 

New Airline

New Airline

Tata, Singapore Air venture Vistara to take off on Jan 9.  Full Article 

Online Sales

Online Sales

Knock knock. Who's there? Amazon's best-selling holiday author.  Full Article 

Hacking Attack

Hacking Attack

N.Korea says did not hack Sony, wants joint probe with U.S.  Full Article 

Reuters Poll

Reuters Poll

BSE Sensex to hit 32,980 by December 2015  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage